Novel Insight of CircRNAs in Cervical Cancer: Potential Biomarkers and Therapeutic Target

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Jul 11

PMID 35814779

Authors

Maomao Wu

Yanxun Han

Xiangfei Gong

Ke Wan

Yuchen Liu

Yi Zhou

Lizhi Zhang

Guozheng Tang

Hui Fang

Bangjie Chen

Fan Yang

Qing Zhao

Genbao Wang

Chenghao Zhanghuang

Yunling Zhang

Affiliations

Soon will be listed here.

Abstract

Cervical cancer (CC) is a prominent cancer around the globe, with a high incidence, and fatality rate. Numerous recent investigations have shown that various non-coding RNAs are associated with the progression of CC. Circular RNAs, a novel class of non-coding RNAs, have a single chain covalent closed-loop structure and are involved in cell growth and other physiological processes. These dysregulated circRNAs seem to have environment-specific functions. They have been demonstrated in certain studies to have a dual involvement in oncogene production and tumor inhibition in different cell settings. Simultaneously, some evidence indicates that circRNAs are abnormally expressed in CC and contributes to its progression. Thus, the distinctive expression profile of circRNAs is associated with the diagnosis, prognosis, and treatment outcomes of CC. We summarized numerous CC-specific circles and their function in revealing the molecular processes of carcinogenesis and progression in CC in this review. Taken together, these data suggest that circRNA may be used as an early detection biomarker and potential therapeutic target in patients with CC.

Citing Articles

Computational analysis of Ayurvedic herbs to explore their potential role as anti-cervical cancer agents.

Dange S, Aggarwal N, Verma R, Sinha Y, Dadhiya S, Mittal G Mol Biol Res Commun. 2025; 14(2):129-141.

PMID: 40028476 PMC: 11865937. DOI: 10.22099/mbrc.2024.51173.2038.

A combination of cuproptosis and lncRNAs predicts the prognosis and tumor immune microenvironment in cervical cancer.

Huang Y, Pan C, Wu S, Ye F, Yang L Discov Oncol. 2024; 15(1):116.

PMID: 38609663 PMC: 11014842. DOI: 10.1007/s12672-024-00964-8.

Molecular aspects of cervical cancer: a pathogenesis update.

Vallejo-Ruiz V, Gutierrez-Xicotencatl L, Medina-Contreras O, Lizano M Front Oncol. 2024; 14:1356581.

PMID: 38567159 PMC: 10985348. DOI: 10.3389/fonc.2024.1356581.

Circular RNAs and cervical cancer: friends or foes? A landscape on circRNA-mediated regulation of key signaling pathways involved in the onset and progression of HPV-related cervical neoplasms.

Heydarnia E, Dorostgou Z, Hedayati N, Mousavi V, Yahyazadeh S, Alimohammadi M Cell Commun Signal. 2024; 22(1):107.

PMID: 38341592 PMC: 10859032. DOI: 10.1186/s12964-024-01494-0.

Hsa_circ_0000069 Accelerates Cervical Cancer Progression by Sponging miR-1270 to Facilitate CPEB4 Expression.

Gong Z, Ge L, Ye S, Xu Y Biochem Genet. 2023; 62(3):1638-1656.

PMID: 37667097 DOI: 10.1007/s10528-023-10494-7.

References

Yang Z, Xie L, Han L, Qu X, Yang Y, Zhang Y . Circular RNAs: Regulators of Cancer-Related Signaling Pathways and Potential Diagnostic Biomarkers for Human Cancers. Theranostics. 2017; 7(12):3106-3117. PMC: 5566109. DOI: 10.7150/thno.19016. View

Wang J, Li H . CircRNA circ_0067934 silencing inhibits the proliferation, migration and invasion of NSCLC cells and correlates with unfavorable prognosis in NSCLC. Eur Rev Med Pharmacol Sci. 2018; 22(10):3053-3060. DOI: 10.26355/eurrev_201805_15063. View

Chen R, Liu H, Yang L, Kang F, Xin L, Huang L . Circular RNA circRNA_0000285 promotes cervical cancer development by regulating FUS. Eur Rev Med Pharmacol Sci. 2019; 23(20):8771-8778. DOI: 10.26355/eurrev_201910_19271. View

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N . Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv72-iv83. DOI: 10.1093/annonc/mdx220. View

Liu J, Wang D, Long Z, Liu J, Li W . CircRNA8924 Promotes Cervical Cancer Cell Proliferation, Migration and Invasion by Competitively Binding to MiR-518d-5p /519-5p Family and Modulating the Expression of CBX8. Cell Physiol Biochem. 2018; 48(1):173-184. DOI: 10.1159/000491716. View

Li H, Wu X, Cheng X . Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016; 27(4):e43. PMC: 4864519. DOI: 10.3802/jgo.2016.27.e43. View

Alinejad V, Somi M, Baradaran B, Akbarzadeh P, Atyabi F, Kazerooni H . Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells. Biomed Pharmacother. 2016; 83:229-240. DOI: 10.1016/j.biopha.2016.06.037. View

Li S, Teng S, Xu J, Su G, Zhang Y, Zhao J . Microarray is an efficient tool for circRNA profiling. Brief Bioinform. 2018; 20(4):1420-1433. DOI: 10.1093/bib/bby006. View

Kontostathi G, Zoidakis J, Anagnou N, Pappa K, Vlahou A, Makridakis M . Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring. Expert Rev Proteomics. 2016; 13(8):731-45. DOI: 10.1080/14789450.2016.1210514. View

10.

Bandyopadhyay A, Basu P, Roy K, Das S, Banerjee S . Treatment of locally advanced carcinoma cervix with special emphasis on brachytherapy: A practice pattern survey among young radiation oncologist of India. South Asian J Cancer. 2018; 7(4):231-235. PMC: 6190401. DOI: 10.4103/sajc.sajc_198_17. View

11.

Daniyal M, Akhtar N, Ahmad S, Fatima U, Akram M, Asif H . Update knowledge on cervical cancer incidence and prevalence in Asia. Asian Pac J Cancer Prev. 2015; 16(9):3617-20. DOI: 10.7314/apjcp.2015.16.9.3617. View

12.

Zygulska A, Krzemieniecki K, Pierzchalski P . Hippo pathway - brief overview of its relevance in cancer. J Physiol Pharmacol. 2017; 68(3):311-335. View

13.

Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J . Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015; 25(8):981-4. PMC: 4528056. DOI: 10.1038/cr.2015.82. View

14.

Ramos-Solano M, Alvarez-Zavala M, Garcia-Castro B, Jave-Suarez L, Aguilar-Lemarroy A . [Wnt signalling pathway and cervical cancer]. Rev Med Inst Mex Seguro Soc. 2015; 53 Suppl 2:S218-24. View

15.

Ma H, Tian T, Liu X, Xia M, Chen C, Mai L . Upregulated circ_0005576 facilitates cervical cancer progression via the miR-153/KIF20A axis. Biomed Pharmacother. 2019; 118:109311. DOI: 10.1016/j.biopha.2019.109311. View

16.

Xu S, Zhou L, Ponnusamy M, Zhang L, Dong Y, Zhang Y . A comprehensive review of circRNA: from purification and identification to disease marker potential. PeerJ. 2018; 6:e5503. PMC: 6110255. DOI: 10.7717/peerj.5503. View

17.

Bei Y, Yang T, Wang L, Holvoet P, Das S, Sluijter J . Circular RNAs as Potential Theranostics in the Cardiovascular System. Mol Ther Nucleic Acids. 2018; 13:407-418. PMC: 6205062. DOI: 10.1016/j.omtn.2018.09.022. View

18.

Wang S, Li Q, Wang Y, Li X, Wang R, Kang Y . Upregulation of circ-UBAP2 predicts poor prognosis and promotes triple-negative breast cancer progression through the miR-661/MTA1 pathway. Biochem Biophys Res Commun. 2018; 505(4):996-1002. DOI: 10.1016/j.bbrc.2018.10.026. View

19.

Fan H, Liu X, Zheng W, Zhuang Z, Wang C . MiR-150 alleviates EMT and cell invasion of colorectal cancer through targeting Gli1. Eur Rev Med Pharmacol Sci. 2017; 21(21):4853-4859. View

20.

Xu Z, Yan Y, Zeng S, Dai S, Chen X, Wei J . Circular RNAs: clinical relevance in cancer. Oncotarget. 2018; 9(1):1444-1460. PMC: 5787450. DOI: 10.18632/oncotarget.22846. View